487 related articles for article (PubMed ID: 33850492)
1. Initial clinical evaluation of indigenous
Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
[No Abstract] [Full Text] [Related]
2. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
5. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
[TBL] [Abstract][Full Text] [Related]
6. The efficacy, toxicity and survival of salvage retreatment PRRT with
Sitani K; Parghane R; Talole S; Basu S
Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
[TBL] [Abstract][Full Text] [Related]
7.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
8. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
9. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of
Basu S; Parghane RV; Naik C
World J Nucl Med; 2020; 19(3):205-210. PubMed ID: 33354174
[TBL] [Abstract][Full Text] [Related]
12. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
15. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
16. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
17. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract][Full Text] [Related]
18. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
20. First-in-Humans Study of the SSTR Antagonist
Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
